Retension (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share, generating expected gross proceeds of $45 million before underwriting discounts, commissions and other offering expenses. The company granted underwriters a 30-day option to purchase up to an additional 562,500 shares. Retension shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, with the offering scheduled to close on or about Oct. 13, subject to customary closing conditions.
Retension intends to use the net proceeds, together with existing cash and cash equivalents, to complete its Phase 2b clinical trial of RTN-001 for uncontrolled hypertension and prepare for, support and advance a planned Phase 3 trial. Remaining funds will be allocated to general corporate purposes and operating expenses. Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are serving as joint bookrunning managers, with Titan Partners acting as lead manager.
To view the full press release, visit https://ibn.fm/uko0m
About Retension Pharmaceuticals
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
For more information, please visit https://www.retensionpharmaceuticals.com/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
